May 15, 2024 – The Lancet Infectious Diseases published article on global burden associated with 85 pathogens in 2019. Helicobacter pylori (H. pylori) is the leading pathogen associated with disease burden in China.

This study estimated disability-adjusted life-years (DALYs) associated with 85 pathogens in 2019, globally, regionally, and for 204 countries and territories. Globally, an estimated 704 million DALYs were associated with 85 different pathogens, including 309 million (43·9% of the burden) in children younger than 5 years. This burden accounted for 27·7% (and 65·5% in those younger than 5 years) of the previously reported total DALYs from all causes in 2019. Three leading pathogens responsible for more than 50 million DALYs each in 2019 were tuberculosis (65·1 million), malaria (53·6 million), and HIV or AIDS (52·1 million). Substantial disease burden was associated with previously less recognized pathogens, including Staphylococcus aureus, Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Acinetobacter baumannii, and H. pylori.

In China, H. pylori was associated with 7.21 million DALYs and was the leading pathogen for disease burden. The second to the fifth pathogens were hepatitis B virus, Staphylococcus aureus, Acinetobacter baumannii and Streptococcus pneumoniae, leading to 6.53 million, 3.76 million, 2.63 million and 2.16 million DALYs in China, respectively.

Link to the article: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00158-0/fulltext.

About TenNor Therapeutics

Incorporated in 2013, TenNor Therapeutics is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address unmet medical needs in disease areas associated with bacterial infections and bacterial metabolism. Empowered by its proprietary multi-targeting conjugate molecule technology, TenNor Therapeutics aims to deliver the best therapeutic solutions to overcome the limitations of conventional treatments and improve patient outcomes. As of July 24, 2025, TenNor Therapeutics had built a differentiated pipeline of seven innovative assets, including three Core Products, namely, rifasutenizol (TNP-2198), the world’s first and only new molecular entity (“NME”) drug candidate developed for the treatment of Helicobacter pylori (“H. pylori”) infection; rifaquizinone (TNP-2092) injection, a potential first-in-class, triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections; and TNP-2092 oral, the world’s first multi-targeting antibacterial drug candidate for the treatment of diseases associated with gut bacterial metabolism.

For more information, please visit: www.tennortherapeutics.com